Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Stressgen (VSE: SSB) -- Ignore unavailable to you. Want to Upgrade?

To: Don Carson who wrote (74)	1/5/1999 6:34:00 PM
From: Heat Shock	Read Replies (1) \| Respond to of 236

To all: list of competition for StressGen's lead product HspE7 for cervical dysplasia and cervical cancer. If you go to this site and do a search for "cervical" and another search for "warts", you get lists of clinical trials for cervical dysplasia and cervical cancer. recap.com There are 7 companies and 11 trials with 2 products on the market. I've added a bit of value by including ticker symbols and home pages. 1 of 7. Developer: Interferon Sciences (IFSC) interferonsciences.com Indication: HIV associated cervical dyplasia Marketer(s): Fujimoto Diagnostics (Japan), Interferon Sciences Product: gel formulation of human leukocyte-derived interferon alfa-n3 Status: Phase 2 in Feb93 Tradename: Alferon N Gel Disease: Infection - AIDS Technology: Natural product Developer: Interferon Sciences Indication: genital warts (condylomata acuminata) Marketer(s): Fujimoto Diagnostics (Japan),Interferon Sciences Product: human leukocyte-derived interferon alfa-n3 (injectable) Status: Market in Feb91 Tradename: Alferon N Injection Disease: Infection - Antibiotics Technology: Natural product The IFSC share price has gone from over $8.00 in Jan98 to about 50 cents . 2 of 7. Developer: Ilex Oncology (ILXO) ilexoncology.com Indication: cervical intraepithelial dysplasias Product: polyamine-forming enzyme inhibitor Status: Phase 2 Tradename: Eflornithine (DFMO - alpha-difluoromethylornithine) Disease: Cancer 3 of 7. Developer: Cantab Pharmaceuticals (CNTBY) noonanrusso.com Indication: cervical cancer Marketer(s): Cantab Pharmaceuticals Product: recombinant vaccinia virus for HPV E6 & E7 Status: Phase 2 Tradename: TA-HPV R&D: Cantab Pharmaceuticals Client: Cancer Research Campaign Disease: Cancer, Infection - Antivirals, Infection - Vaccines Technology: Recombinant DNA Developer: Cantab Pharmaceuticals Indication: HSV-2 (genital warts) Marketer(s): SmithKline Product: immunotherapeutic vaccine Status: Phase II in May96 Tradename: TA-GW Disease: Infection - Antivirals, Infection - Vaccines Technology: Recombinant DNA 4 of 7. Developer: Biogen (BGEN) biogen.com Indication: cervical dysplasia Marketer(s): Biogen Product: recombinant human beta interferon 1-a (glycosylated) Status: Phase 2 Tradename: Avonex Disease: Cancer Technology: Recombinant DNA I cannot find anything more on Avonex trial against cervical dysplasia. Developer: Biogen Indication: condylomata acuminata (genital warts) Marketer(s): Schering-Plough Product: human recombinant interferon alpha 2-b Status: Market in Jun88 Tradename: Intron-A Disease: Infection - Antibiotics Technology: Recombinant DNA Developer: Biogen Indication: venereal warts Marketer(s): Biogen Product: recombinant human gamma interferon Status: Phase II Tradename: Immuneron Disease: Infection - Antivirals Technology: Recombinant DNA 5 of 7. Developer: MedImmune (MEDI) medimmune.com Indication: prevention of genital herpes (HPV) Marketer(s): SmithKline Product: vaccine of VLPs from HPV-11 L1 capsid protein Status: Phase 1 in Feb97 Tradename: MEDI-501 Disease: Infection - Antivirals, Infection - Vaccines Technology: Recombinant DNA MEDIMMUNE FINALIZES VACCINE AGREEMENT with SmithKline Beecham (SBH) medimmune.com A page on the MEDI web site, medimmune.com says "The Company began a Phase 1 clinical trial with MEDI-501 in February 1997 to evaluate its safety, tolerance, and immunogenicity. The trial, which is being conducted at the University of Rochester Medical Center, is expected to conclude by year-end. In addition, the Company has an HPV-18 vaccine candidate (MEDI-504) and an HPV-16 vaccine candidate (MEDI-503) in pre-clinical development." I cannot find anything more on these trials. 6 of 7. Developer: Cytel (CYTL) subsidiary "Epimmune" cytelcorp.com Indication: late-stage cervical cancer Marketer(s): Cytel Product: human papillomarirus (HPV) antigenic peptide-based therapeutic vaccine Status: Phase 1-2 Tradename: CY-2121 Theradigm-HPV Disease: Cancer, Infection - Vaccines Technology: Recombinant DNA CYTL share price has gone from $60.00 in mid-96 to about $2.50 today. 7 of 7. Developer: Gilead (GILD) gilead.com Indication: HPV-associated genital warts Marketer(s): Gilead Product: nucleotide analog (cidofovir topical gel) Status: Phase I/II Phase 2 in Mar96. Tradename: Forvade Disease: Infection - Antivirals Technology: Synthetics Note: GILD's web site tried 84 times to put a cookie on my PC. A quick look at the web site shows nothing about this trial. Heat.